Chief Investigator: Professor Val Jenkins
Co-Investigators: Professor Dame Lesley Fallowfield, Professor Heather Payne, Professor Malcolm Mason
Investigator Sponsored Study funded by Aventis Pharma Limited trading as Sanofi
Currently there are insufficient data from patient reported outcomes regarding the impact of treatments in men with metastatic castrate resistant prostate cancer (mCRPC) and factors that drive decision-making about the treatments. Our study will examine both the patients' and health care professionals' perspectives to explore any gaps and inconsistencies.